gsk-2126458 and Carcinogenesis

gsk-2126458 has been researched along with Carcinogenesis* in 2 studies

Other Studies

2 other study(ies) available for gsk-2126458 and Carcinogenesis

ArticleYear
The PI3K/mTOR dual inhibitor GSK458 potently impedes ovarian cancer tumorigenesis and metastasis.
    Cellular oncology (Dordrecht), 2020, Volume: 43, Issue:4

    The PI3K/AKT/mTOR pathway is one of the most highly activated cellular signaling pathways in advanced ovarian cancer. Although several PI3K/AKT/mTOR inhibitors have been developed to treat various types of cancer, the antitumor efficacy of many of these compounds against ovarian cancer has remained unclear.. Here, we tested and compared a panel of 16 PI3K/AKT/mTOR inhibitors (XL765, Miltefosine, Rapamycin, CCI-779, RAD001, FK506, XL147, GSK2110183, IPI-145, GSK2141795, BYL719, GSK458, CAL-101, XL765 analogue SAR245409, Triciribine, and GDC0941) that have entered clinical trials for antitumor activity against ovarian cancer, as well as the front line drug, paclitaxel. Antitumor efficacy was measured in both ovarian cancer cell lines and patient-derived ovarian primary tumor cell lines in vitro and in vivo.. Based on our results, we conclude that GSK458 may serve as an attractive candidate to treat ovarian cancer.

    Topics: Animals; Carcinogenesis; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Female; Humans; Mice; Mice, Nude; Ovarian Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Pyridazines; Quinolines; Sulfonamides; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays

2020
Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2.
    PloS one, 2018, Volume: 13, Issue:6

    Neurofibromatosis 2 (NF2) is a rare tumor suppressor syndrome that manifests with multiple schwannomas and meningiomas. There are no effective drug therapies for these benign tumors and conventional therapies have limited efficacy. Various model systems have been created and several drug targets have been implicated in NF2-driven tumorigenesis based on known effects of the absence of merlin, the product of the NF2 gene. We tested priority compounds based on known biology with traditional dose-concentration studies in meningioma and schwann cell systems. Concurrently, we studied functional kinome and gene expression in these cells pre- and post-treatment to determine merlin deficient molecular phenotypes. Cell viability results showed that three agents (GSK2126458, Panobinostat, CUDC-907) had the greatest activity across schwannoma and meningioma cell systems, but merlin status did not significantly influence response. In vivo, drug effect was tumor specific with meningioma, but not schwannoma, showing response to GSK2126458 and Panobinostat. In culture, changes in both the transcriptome and kinome in response to treatment clustered predominantly based on tumor type. However, there were differences in both gene expression and functional kinome at baseline between meningioma and schwannoma cell systems that may form the basis for future selective therapies. This work has created an openly accessible resource (www.synapse.org/SynodosNF2) of fully characterized isogenic schwannoma and meningioma cell systems as well as a rich data source of kinome and transcriptome data from these assay systems before and after treatment that enables single and combination drug discovery based on molecular phenotype.

    Topics: Animals; Carcinogenesis; Cell Line, Tumor; Cell Survival; Gene Expression Regulation, Neoplastic; Humans; Meningeal Neoplasms; Mice; Morpholines; Neurilemmoma; Neurofibromatosis 2; Neurofibromin 2; Panobinostat; Pyridazines; Pyrimidines; Quinolines; Sulfonamides; Systems Biology; Transcriptome

2018